About Corvus Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.corvuspharma.com/
Frequently Asked Questions
What is the 52-week range for CRVS?
The 52-week high is $26.95 and the 52-week low is $6.39.
What is the P/E ratio for CRVS?
The P/E ratio data is currently unavailable.
What is the dividend yield for CRVS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -36.15%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 9.40.
Analyst Recommendation Trends
Wall Street analyst consensus for CRVS over the last few months:
Latest CRVS News
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa
Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biologySOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa. “The initiation of our Phase 1b hidrade
Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?
Corvus Pharmaceuticals (CRVS) has drawn fresh attention after recent trading left the biotech down about 19% over the past month and 13% over the past 3 months from a US$11.80 close. That recent slide sits against a much stronger ride for Corvus Pharmaceuticals, with the share price return still up 61.2% year to date and the 1 year total shareholder return at 78.52%, while the 3 year total shareholder return is very large at roughly 7x. This indicates strong long term momentum even as short...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-11 | Moore David Scott | +15,000 | - | - |
| 2026-06-11 | Moore David Scott | +21,700 | $11.5316 | $250,236 |
| 2026-06-11 | van den Broek Richard | +15,000 | - | - |
| 2026-06-11 | Grais Linda | +15,000 | - | - |
| 2026-06-11 | Thompson Peter A. | +15,000 | - | - |
| 2026-06-11 | CLARK IAN T | +15,000 | - | - |
| 2026-05-18 | MILLER RICHARD A MD | +1,932 | $12.01 | $23,203 |
| 2026-05-18 | MILLER RICHARD A MD | +5,000 | $12.05 | $60,250 |
| 2026-04-23 | Chan Andrew C. | +30,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -15,000 | - | - |
| 2026-01-28 | Thompson Peter A. | -30,000 | - | - |
| 2026-01-28 | Thompson Peter A. | +15,000 | $2.12 | $31,800 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $1.64 | $24,600 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $2.49 | $37,350 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $0.965 | $14,475 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $0.9899 | $14,849 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $2.6 | $39,000 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $2.74 | $41,100 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $3.27 | $49,050 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $2 | $30,000 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $3.61 | $54,150 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $12.5 | $187,500 |
| 2026-01-28 | Thompson Peter A. | +15,000 | $9.7 | $145,500 |
| 2026-01-28 | Thompson Peter A. | +30,000 | $15 | $450,000 |
| 2025-12-04 | Jones William Benton | +400,000 | - | - |
| 2025-12-04 | Arcara Jeffrey | +100,000 | - | - |
| 2025-12-04 | LEA LEIV | +400,000 | - | - |
| 2025-12-04 | MILLER RICHARD A MD | +1,000,000 | - | - |